Breaking News Instant updates and real-time market news.

FCX

Freeport McMoRan

$13.20

-0.11 (-0.83%)

, DB

Deutsche Bank

$19.35

-0.86 (-4.26%)

07:31
03/06/17
03/06
07:31
03/06/17
07:31

Unusual put flow in option market yesterday

Notable put activity was cited Friday in Freeport McMoRan (FCX), Deutsche Bank (DB), Southwest (LUV), Abbott (ABT), Exelixis (EXEL), Carnival (CCL), and MiMedx (MDXG).

FCX

Freeport McMoRan

$13.20

-0.11 (-0.83%)

DB

Deutsche Bank

$19.35

-0.86 (-4.26%)

LUV

Southwest

$58.86

1.29 (2.24%)

ABT

Abbott

$45.25

-0.44 (-0.96%)

EXEL

Exelixis

$23.08

1.09 (4.96%)

CCL

Carnival

$55.72

-0.85 (-1.50%)

MDXG

MiMedx

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 16

    Mar

  • 16

    Mar

  • 17

    Mar

FCX Freeport McMoRan
$13.20

-0.11 (-0.83%)

02/21/17
DBAB
02/21/17
DOWNGRADE
Target $12.5
DBAB
Sell
Freeport McMoRan downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Freeport McMoRan to Sell following news that the company failed to reach an agreement to export copper concentrate from Indonesia. The analyst now assumes that Grasberg operates on scaled-back mode, only supplying the local Gresik smelter for the remainder of 2017. He cut his price target for Freeport shares to $12.50 from $14.
02/21/17
SBSH
02/21/17
INITIATION
Target $16
SBSH
Neutral
Freeport McMoRan initiated with a Neutral at Citi
Citi analyst Alexander Hacking started Freeport McMoRan with a Neutral rating and $16 price target. The analyst finds the stock fully value amid uncertainties around Grasberg.
02/21/17
02/21/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap Inc (SNAP) initiated with a Neutral rating and a $14 price target at Atlantic Equities, who said that expansion beyond the core audience is likely challenging, sustainability of engagement concerns will persist, and margins are structurally lower than peers. 2. REV Group (REVG) initiated with an Outperform at Credit Suisse. 3. Nokia (NOK) initiated with a Buy at Craig-Hallum. 4. Freeport McMoRan (FCX) initiated with a Neutral at Citi. 5. Jounce Therapeutics (JNCE) initiated with an Outperform at Cowen, with an Outperform at Wells Fargo and with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/21/17
02/21/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dick's Sporting (DKS) downgraded to Perform from Outperform at Oppenheimer by analyst Brian Nagel ahead of its upcoming earnings report, as he is increasingly concerned after a large number of leading sporting goods manufacturers and retailers reported results well shy of expectations, all while certain industry-wide sales trackers also hinted at top-line disruptions for the sector. 2. Mobileye (MBLY) downgraded to Neutral from Buy, as analyst Alex Veytsman said expectations are high and valuation largely reflects its strong growth profile. 3. Freeport McMoRan (FCX) downgraded to Sell from Hold at Deutsche Bank by analyst Chris Terry following news that the company failed to reach an agreement to export copper concentrate from Indonesia. The analyst now assumes that Grasberg operates on scaled-back mode, only supplying the local Gresik smelter for the remainder of 2017. He cut his price target for Freeport shares to $12.50 from $14. 4. Lumos Networks (LMOS) downgraded to Hold from Buy at Jefferies by analyst Scott Goldman citing the takeover by EQT Infrastructure, stating he does not expect any competing bids and sees "virtually no deal risk from a regulatory standpoint." 5. Depomed (DEPO) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DB Deutsche Bank
$19.35

-0.86 (-4.26%)

09/29/16
COWN
09/29/16
NO CHANGE
COWN
DoJ will not destabilize Deutsche Bank, says Cowen
Cowen analyst Jaret Seiberg sees little practical or political upside for the Justice Department to press Deutsche Bank for a penalty that is so large it could destabilize the bank and create a new financial crisis. He expects the penalty for violations related to mortgage-backed securities to be structured below the speculated $14B that seems to have alarmed the market. Seiberg adds both sides have incentives to reach a deal quickly.
01/06/17
01/06/17
UPGRADE
Target $67

Outperform
Luxoft upgraded to Outperform at Wedbush
As previously reported, Wedbush analyst Moshe Katri upgraded Luxoft (LXFT) to Outperform from Neutral to reflect not only an improving spending outlook for the Financial Services sector, but also spending improvements at UBS (UBS) and Deutsche Bank (DB), which collectively account for roughly 43% of the company's revenue base. He also raised his price target on the shares to $67 from $62.
12/19/16
SBSH
12/19/16
DOWNGRADE
SBSH
Sell
Deutsche Bank downgraded to Sell from Neutral at Citi
Citi analyst Andrew Coombs downgraded Deutsche Bank to Sell saying the shares have run "too far, too fast." Since the U.S. election, the stock is up 41%, Coombs tells investors in a research note. The further the share price rises, the less dilutive any future potential capital raise becomes, the analyst writes. He raised his price target for Deutsche shares to EUR 17 from EUR 15.
09/30/16
09/30/16
NO CHANGE

Correction: Deutsche Bank credit upgraded to Neutral at BofA/Merrill
BofA/Merrill upgraded Deutsche Bank's credit to Neutral, not the equity.
LUV Southwest
$58.86

1.29 (2.24%)

01/25/17
JPMS
01/25/17
UPGRADE
Target $27
JPMS
Overweight
JetBlue upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jamie Baker upgraded JetBlue (JBLU) to Overweight saying the shares are the cheapest among the domestic airlines. The stock is trading at a nearly five-turn discount to both Southwest (LUV) and Spirit Airlines (SAVE) on the analyst's 2017 estimates. The analyst suggests out of Southwest and into JetBlue. He raised his price target for the latter to $27 from $21. Baker this morning also downgraded Southwest to Neutral.
01/25/17
01/25/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Verizon (VZ) was downgraded to Sector Perform from Outperform at RBC Capital, to Market Perform from Outperform at FBR Capital, and to Market Perform from Outperform at Raymond James. 2. Vodafone (VOD) downgraded to Neutral from Buy at BofA/Merrill with analyst David Wright citing accelerating headwinds and lack of near-term catalysts. 3. Coach (COH) was downgraded to Neutral from Overweight at Atlantic Equities and to Outperform from Buy at CLSA. 4. Kate Spade (KATE) downgraded to Market Perform from Outperform at Telsey Advisory with analyst Dana Telsey saying Kate Spade shares are up 32% over the past month on persistent press reports of a possible takeout. Strategic deals of this scope in the group have been few and far between lately, while financial deals have struggled to raise the necessary funding in the mall-based fashion group, in Telsey's view. With the takeout speculation unlocking most of the value she sees in the brand, the analyst believes valuation reflects a risk discount to a deal that would likely be in a low $20-range. 5. Southwest (LUV) downgraded to Neutral from Overweight at JPMorgan with analyst Jamie Baker saying the shares look less attractive at $50. The analyst recommends swapping into JetBlue (JBLU), a stock he upgraded this morning to Overweight. Baker raised his price target for Southwest shares to $55 from $51.50. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/25/17
JPMS
01/25/17
DOWNGRADE
Target $55
JPMS
Neutral
Southwest downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jamie Baker downgraded Southwest Airlines (LUV) to Neutral saying the shares look less attractive at $50. The analyst recommends swapping into JetBlue (JBLU), a stock he upgraded this morning to Overweight. Baker raised his price target for Southwest shares to $55 from $51.50.
02/22/17
02/22/17
NO CHANGE

Morgan Stanley would not dismiss possibility of Berkshire buying an airline
With Warren Buffett's Berkshire Hathaway (BRK.A) recently disclosing an increase to its overall airline exposure, making the firm a number one or two holder for each of the "Big 4," Morgan Stanley polled investors and found that about 60% do not expect this to be a step towards a full-scale acquisition. However, analyst Rajeev Lalwani said the prospect of Berkshire buying an airline is a possibility that is "not worth dismissing," citing the historical precedent of Buffett's involvement in the rail industry and eventual deal to buy Burlington Northern SantaFe in 2009. The top four U.S. airlines include American Airlines (AAL), Delta Air Lines (DAL), Southwest (LUV) and United Continental (UAL).
ABT Abbott
$45.25

-0.44 (-0.96%)

12/08/16
ADAM
12/08/16
NO CHANGE
Target $52
ADAM
Buy
Legal rights in favor of Alere in buyout fight, says Canaccord
Canaccord analyst Mark Massaro noted Abbot (ABT) filed a lawsuit to terminate its acquisition of Alere (ALR), which sent the latter's stock below where it was prior to the original deal being struck. The analyst said the legal jurisdiction is in Delaware, which heavily favors Alere, who said they will take whatever actions are necessary to make Abbott complete the transaction. Alere is confident the deal will be completed at the agreed upon terms, with the company in a good position to have its Arriva Medical business reimbursement restored by the CMS, said Massaro, who raised his price target to $52 from $50 and reiterated his Buy rating on Alere shares.
12/19/16
12/19/16
UPGRADE
Target $84

Outperform
Dexcom upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Steven Lichtman upgraded Dexcom (DXCM) to Outperform from Perform, with an $84 price target, given valuation reflecting competitive concerns and big long-term opportunities in place. While new competition in the U.S. is expected from Medtronic (MDT) and likely Abbott (ABT) and Senseonics (SENS) in 2017, the analyst believes the CGM market remains underpenetrated in Type 1 patients, a dosing claim is expected early 2017, international reimbursement should be a growing tailwind and 2018 brings new growth drivers with expected launch of Dexcom's next-generation G6 and potential Medicare expansion.
03/01/17
RAJA
03/01/17
NO CHANGE
RAJA
Market Perform
Alere filing delay should not be surprise, says Raymond James
Raymond James analyst Nicholas Jansen says that while the annual filing delay is not a headline Alere (ALR) shareholders wanted to see given the company's current battle with Abbott (ABT), the revision just relates to timing, not "bad revenue," and is immaterial in totality relative to a $2.5B revenue base. Alere's annual filing was unlikely to include a full remediation of internal control weakness, so this issue, while disappointing, should not be a surprise, Jansen tells investors in a research note. He keeps a Market Perform rating on the shares. Alere in early trading is down 3%, or $1.27, to $37.03.
01/23/17
COWN
01/23/17
NO CHANGE
Target $48
COWN
Outperform
Abbott valuation compelling and discount may not last long, says Cowen
Cowen analyst Joshua Jennings said Abbott's valuation is currently at a compelling discount, but that may not last long. He said the Abbott/St. Jude Medical combination has given him conviction the combined company can sustain greater than 5% organic growth and 12-15% earnings growth in 2018 to 2020. Jennings reiterated his Outperform rating and $48 price target on Abbott shares.
EXEL Exelixis
$23.08

1.09 (4.96%)

01/31/17
01/31/17
NO CHANGE

Exelixis down with licensing deal seen as impacting takeover potential
Shares of Exelixis (EXEL) are moving lower after the company last night announced a licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, its oncology medicine, with Takeda Pharmaceutical (TKPYY). Deutsche Bank analyst Andrew Peters said earlier today that while Exelixis' licensing agreement is "clearly encouraging" and highlights the value of cabozantinib, the news could impact "near-term expectations regarding strategic activity, as Japanese rights would be similarly valuable to maintain." Exelixis is down 4%, or 66c, to $17.62 in afternoon trading, a sign that the deal with Takeda could be dampening investor expectations of a buyout in the near-term. The company maintaining the U.S. rights is key, Peters told investors in a research note, adding that the U.S. is core to the valuation and the company's strategic positioning. The analyst has a Buy rating on Exelixis with a $20 price target.
02/28/17
02/28/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Workday (WDAY) downgraded to Sell from Neutral at Citi and to Hold from Buy at Evercore ISI. 2. Exelixis (EXEL) downgraded to Hold from Buy at Stifel with analyst Stephen Willey citing valuation. 3. Teva (TEVA) downgraded to Hold from Buy at Argus. 4. Cabot Oil & Gas (COG) downgraded to Market Perform from Outperform at Bernstein. 5. HP Enterprise (HPE) downgraded to Hold from Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/28/17
LEER
02/28/17
NO CHANGE
Target $26
LEER
Outperform
Exelixis price target raised to $26 from $20 at Leerink
Leerink analyst Michael Schmidt raised his price target for Exelixis to $26 from $20 after the company reported "another strong quarter" driven by strong product sales growth, which was in-line with expectations, and milestone payments above expectations. The analyst reiterates an Outperform rating on the shares.
02/28/17
STFL
02/28/17
DOWNGRADE
Target $22
STFL
Hold
Exelixis downgraded to Hold from Buy at Stifel
Stifel analyst Stephen Willey downgraded Exelixis to Hold citing valuation and raised the price target on shares to $22 from $21 following the Q4 beat.
CCL Carnival
$55.72

-0.85 (-1.50%)

02/27/17
02/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Steven Madden (SHOO) upgraded to Buy from Neutral at B. Riley by analyst Jeff Van Sinderen, who said last week's footwear show and latest channel checks underscore the company's potential for growth. 2. Illumina (ILMN) upgraded to Buy from Hold at Evercore ISI by analyst Ross Muken following customer checks that lead him to above consensus revenue forecasts. Muken believes Illumina will sell 750-1,300 NovaSeq boxes over the next several years as sequencing enters a new era of utility. 3. Carnival (CCL) upgraded Buy from Hold by Argus analyst John Staszak, who now believes that "continued " improvement in demand for cruises will improve the company's earnings and margins. 4. Cempra (CEMP) upgraded to Buy at Roth Capital by analyst Michael Higgins after the company announced positive Phase 3 results in the first of two skin infection studies with Taksta, and ahead of bone data in 2017. The analyst also raised his price target on the shares to $8 from $2.50. 5. Unilever (UN) upgraded to Neutral from Underperform at BofA Merrill Lynch by analyst David Hayes, citing valuation and his belief that the strategic review could accelerate margin development targets over the next 4 years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/27/17
ARGS
02/27/17
UPGRADE
ARGS
Buy
Carnival upgraded on demand outlook at Argus
As noted earlier, Argus upgraded Carnival to Buy from Hold. Analyst John Staszak says that he now believes that "continued " improvement in demand for cruises will improve the company's earnings and margins. Target $64.
02/27/17
ARGS
02/27/17
UPGRADE
ARGS
Buy
Carnival upgraded to Buy from Hold at Argus
02/23/17
FBCO
02/23/17
NO CHANGE
Target $67
FBCO
Outperform
Carnival price target raised to $67 from $60 at Credit Suisse
Credit Suisse analyst Tim Ramskill raised his price target for Carnival to $67 from $60 as yield momentum, cost discipline and excess cash returns outweigh supply. The analyst reiterates an Outperform rating on the shares.
MDXG MiMedx

03/03/17
PIPR
03/03/17
INITIATION
Target $10
PIPR
Overweight
MiMedx initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien initiated MiMedx with an Overweight rating and $10 price target, calling it market leader for amniotic-based products that also has a large, untapped opportunity in pain management.
12/12/16
UBSW
12/12/16
INITIATION
Target $9
UBSW
Sell
MiMedx initiated with a Sell at UBS
UBS analyst Matt Miksic started MiMedx Group with a Sell rating and $9 price target. The analyst says his firm's survey of 100 U.S. wound care specialists suggests Integra LifeSciences' (IART) Omnigraft launch will put competitive pressure on MiMedx's EpiFix over time. The stock at current levels is not discounting significant market share losses or decelerating growth, Miksic tells investors in a research note.
12/12/16
FANA
12/12/16
NO CHANGE
FANA
Equal-Weight
First Analysis says reimbursement has favored MiMedx, but uncertainty exists
Under the current per-treatment reimbursement system, MiMedx (MDXG) has been a "powerhouse in wound care," taking share with its EpiFix product line, and current structure of the market naturally benefits MiMedx's business model, First Analysis analyst Joseph Munda tells investors. However, the FDA is reviewing the use and regulatory status of amniotic tissues in wound care and FDA action would raise their cost or limit their use, which is a risk for MiMedx that would likely benefit other advanced tissues, including Novadaq's (NVDQ) Dermacell, he contends. Munda keeps an Equal-Weight rating on MiMedx, citing regulatory uncertainties, and has an rate Overweight rating on Novadaq.
12/12/16
12/12/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ball Corp. (BLL) resumed with a Buy at Deutsche Bank. 2. Molson Coors (TAP) initiated with a Neutral at UBS. 3. Airgain (AIRG) initiated with an Outperform at Cowen. 4 Ritter Pharmaceuticals (RTTR) initiated with a Buy at Roth Capital. 5. MiMedx (MDXG) initiated with a Sell at UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

12:20
03/23/17
03/23
12:20
03/23/17
12:20
General news
FX Action: USD-JPY has bounced »

FX Action: USD-JPY has…

GCI

Gannett

$8.21

0.09 (1.11%)

12:20
03/23/17
03/23
12:20
03/23/17
12:20
Conference/Events
Gannett management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

$NSD

NASDAQ Market Internals

12:17
03/23/17
03/23
12:17
03/23/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TISA

Top Image Systems

$1.24

-0.0212 (-1.68%)

12:16
03/23/17
03/23
12:16
03/23/17
12:16
Hot Stocks
Breaking Hot Stocks news story on Top Image Systems »

Palogic Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
03/23/17
03/23
12:16
03/23/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
03/23/17
03/23
12:15
03/23/17
12:15
General news
Treasury Action: bonds are in limbo awaiting results the House ACA vote »

Treasury Action: bonds…

12:15
03/23/17
03/23
12:15
03/23/17
12:15
General news
Breaking General news story  »

Minneapolis Federal…

Z

Zillow

$35.29

0.12 (0.34%)

12:11
03/23/17
03/23
12:11
03/23/17
12:11
Options
Bearish flow in Zillow as shares falter »

Bearish flow in Zillow as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

12:10
03/23/17
03/23
12:10
03/23/17
12:10
General news
U.S. equities are dusting themselves off »

U.S. equities are dusting…

ATEC

Alphatec

$2.68

-0.12 (-4.29%)

12:08
03/23/17
03/23
12:08
03/23/17
12:08
Syndicate
Alphatec announces $18.9M private placement »

H.C. Wainwright is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OA

Orbital ATK

$99.47

-0.075 (-0.08%)

12:08
03/23/17
03/23
12:08
03/23/17
12:08
Periodicals
SSL sues Orbital ATK over claims of confidential data theft, Reuters says »

Space Systems/Loral has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

TRIP

TripAdvisor

$41.40

-0.31 (-0.74%)

, PCLN

Priceline

$1,751.99

4.85 (0.28%)

12:06
03/23/17
03/23
12:06
03/23/17
12:06
Hot Stocks
TripAdvisor strength attributed to takeover speculation »

The intraday move up in…

TRIP

TripAdvisor

$41.40

-0.31 (-0.74%)

PCLN

Priceline

$1,751.99

4.85 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:01
03/23/17
03/23
12:01
03/23/17
12:01
Conference/Events
Stephens transportation analysts hold an analyst/industry conference call »

Transportation Analysts…

BAC

Bank of America

$23.34

0.4 (1.74%)

12:01
03/23/17
03/23
12:01
03/23/17
12:01
Options
Today's four most active single stock options are calls on BofA »

Today's four most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$270.93

1.51 (0.56%)

12:01
03/23/17
03/23
12:01
03/23/17
12:01
Hot Stocks
Lockheed Martin to expand production for F-35 components in Johnstown »

Lockheed Martin will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

CEO

CNOOC

$118.68

3.25 (2.82%)

11:59
03/23/17
03/23
11:59
03/23/17
11:59
Upgrade
CNOOC rating change  »

CNOOC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POL

PolyOne

$33.38

0.47 (1.43%)

11:59
03/23/17
03/23
11:59
03/23/17
11:59
Conference/Events
PolyOne management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

  • 27

    Mar

GRBK

Green Brick

11:56
03/23/17
03/23
11:56
03/23/17
11:56
Hot Stocks
Green Brick Partners director acquires 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLXN

Flexion

$19.68

0.14 (0.72%)

, SNY

Sanofi

$45.09

0.42 (0.94%)

11:56
03/23/17
03/23
11:56
03/23/17
11:56
Recommendations
Flexion, Sanofi analyst commentary  »

Flexion CFO departure…

FLXN

Flexion

$19.68

0.14 (0.72%)

SNY

Sanofi

$45.09

0.42 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 10

    May

  • 06

    Oct

SAN

Banco Santander

$6.12

0.005 (0.08%)

11:55
03/23/17
03/23
11:55
03/23/17
11:55
Hot Stocks
Santander to improve consumer protections in Fed agreement »

Santander has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
03/23/17
03/23
11:55
03/23/17
11:55
Conference/Events
Federal Reserve Bank of Minneapolis President speaks at conference »

Minneapolis Federal…

MAA

MAA

$101.99

0.72 (0.71%)

11:54
03/23/17
03/23
11:54
03/23/17
11:54
Conference/Events
MAA management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

ADP

ADP

$103.68

0.56 (0.54%)

, CSOD

Cornerstone OnDemand

$38.36

-0.14 (-0.36%)

11:53
03/23/17
03/23
11:53
03/23/17
11:53
Conference/Events
Stephens enterprise software analysts hold an analyst/industry conference call »

Enterprise Software…

ADP

ADP

$103.68

0.56 (0.54%)

CSOD

Cornerstone OnDemand

$38.36

-0.14 (-0.36%)

ORCL

Oracle

$44.97

0.175 (0.39%)

PAYC

Paycom

$54.22

-1.06 (-1.92%)

PCTY

Paylocity

$35.16

-0.16 (-0.45%)

SAP

SAP

$98.09

0.44 (0.45%)

ULTI

Ultimate Software

$193.35

1.24 (0.65%)

WDAY

Workday

$81.64

0.19 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 09

    May

  • 08

    Jun

  • 20

    Jun

TRP

TransCanada

$46.42

0.25 (0.54%)

11:52
03/23/17
03/23
11:52
03/23/17
11:52
Periodicals
State Department expected to approve Keystone XL pipeline permit, Politico says »

The U.S. State Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$10.02

-0.1 (-0.99%)

11:51
03/23/17
03/23
11:51
03/23/17
11:51
Options
Vote of confidence in the US Oil Fund »

Vote of confidence in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.